Go Back

Literature in Oncology: Lymphomas

Chen B, Han D, Ge BH, Li C, Ma D, Yang J.

The diagnostic performance of 18F-FDG PET in detecting bone marrow infiltration in Hodgkin's lymphoma and diffuse large B-cell lymphoma: a meta-analysis.

Skeletal Radiol. 2014 Sep 7.


Metser U, Hussey D, Murphy G.

Impact of <sup>18</sup>F-FDG PET/CT on the staging and management of follicular lymphoma.

Br J Radiol. 2014 Sep 2:20140360.


Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD.

Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

J Clin Oncol. 2014 Aug 11.


Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification.

J Clin Oncol. 2014  Aug 11.


Pardal E, Coronado M, Martín A, Grande C, Marín-Niebla A, Panizo C, Bello JL, Conde E, Hernández MT, Arranz R, Bargay J, González-Barca E, Pérez-Ceballos E, Montes-Moreno S, Caballero MD.

Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.

Br J Haematol. 2014 Jul 28.


Cuccaro A, Bartolomei F, Cupelli E, Galli E, Giachelia M, Hohaus S.

Prognostic factors in hodgkin lymphoma.

Mediterr J Hematol Infect Dis. 2014 Jul 5;6(1):e2014053. 


PDFFree pdf

Martelli M, Ceriani L, Zucca E, Zinzani PL, Ferreri AJ, Vitolo U, Stelitano C, Brusamolino E, Cabras MG, Rigacci L, Balzarotti M, Salvi F, Montoto S, Lopez-Guillermo A, Finolezzi E, Pileri SA, Davies A, Cavalli F, Giovanella L, Johnson PW.

[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.

J Clin Oncol. 2014 Jun 10;32(17):1769-75.


Kostakoglu L, Cheson BD.

Current role of FDG PET/CT in lymphoma.

Eur J Nucl Med Mol Imaging. 2014 May;41(5):1004-27.


Adams HJ, Kwee TC, de Keizer B, Fijnheer R, de Klerk JM, Littooij AS, Nievelstein RA.

Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary?

Ann Oncol. 2014 May;25(5):921-7.


Mhlanga JC, Durand D, Tsai HL, Durand CM, Leal JP, Wang H, Moore R, Wahl RL.

Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry.

Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):596-604.


Tychyj-Pinel C, Ricard F, Fulham M, Fournier M, Meignan M, Lamy T, Vera P, Salles G, Trotman J.

PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study.

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):408-15.


Annunziata S, Caldarella C, Treglia G.

Cost-effectiveness of Fluorine-18-Fluorodeoxyglucose positron emission tomography in tumours other than lung cancer: A systematic review.

World J Radiol. 2014 Mar 28;6(3):48-55.


PDFFree pdf

Kostakoglu L, Evens AM.

FDG-PET imaging for Hodgkin lymphoma: current use and future applications.

Clin Adv Hematol Oncol. 2014 Jan;12(1):20-35.


Gu J, Chan T, Zhang J, Leung AY, Kwong YL, Khong PL.

Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma.

AJR Am J Roentgenol. 2011 Sep;197(3):W384-91.


Pommier P, Dussart S, Girinsky T, Chabaud S, Lagrange JL, Nguyen TD, Beckendorff V, D'Hombres A, Artignan X, Bondiau PY, Carrie C, Giammarile F.

Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study.

Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):823-8.


Vera P, Ouvrier MJ, Hapdey S, Thillays M, Pesquet AS, Diologent B, Callonec F, Hitzel A, Edet-Sanson A, Ménard JF, Jardin F, Tilly H.

Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma?

Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1943-52.


Strobel K, Pestalozzi B, Ciernik I, Schaefer NG, Koma AY, Hany TF.

Changing PET/CT manifestation of neurolymphomatosis.

Eur J Nucl Med Mol Imaging. 2006 Oct;33(10):1244. Epub 2006 Jul 6.